Ethionamide is an oral antibiotic used to treat tuberculosis (TB), particularly active multidrug-resistant tuberculosis (MDR-TB), when used in combination with other anti-TB medications. It works by inhibiting the synthesis of mycolic acids, essential components of the mycobacterial cell wall, leading to the destruction of the bacteria.
Although it was previously used for leprosy, ethionamide is no longer recommended for this purpose due to its limited efficacy and high rate of side effects.
Parent: Ethionamide
Parent: Ethionamide
Parent: Ethionamide
Parent: Ethionamide
As with all pharmaceutical products, impurities may develop in ethionamide during its manufacturing, storage, or handling. Regulatory authorities enforce strict guidelines to monitor and control these impurities, ensuring the medication’s safety, efficacy, and quality.
Related Substances
These are chemically related compounds or byproducts formed during the synthesis of ethionamide. Monitoring related substances ensures the drug’s purity and therapeutic effectiveness.
Degradation Products
Ethionamide may degrade over time when exposed to environmental factors like light, heat, or moisture. Proper storage in a cool, dry place is essential to maintain its stability.
Residual Solvents
Trace amounts of solvents used during the manufacturing process may remain in the final product. Regulatory standards ensure these solvents are within permissible limits to minimize risks to patients.
Analytical Techniques for Monitoring Impurities
Techniques such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (LC-MS) are commonly used to detect and quantify impurities, ensuring ethionamide meets stringent safety and quality standards.
Ethionamide is used to treat active multidrug-resistant tuberculosis (MDR-TB) in combination with other anti-TB medications. It is effective against mycobacteria by inhibiting their cell wall synthesis.
No, ethionamide is not a first-line drug. It is considered a second-line drug for the treatment of tuberculosis, primarily reserved for cases of multidrug-resistant TB or when first-line drugs are not effective.
Yes, ethionamide is classified as a second-line drug for tuberculosis. It is used in combination with other medications to treat multidrug-resistant TB.
Ethionamide was previously used in the treatment of leprosy, but it is no longer recommended due to its limited efficacy and significant side effects. Alternative medications are now preferred for managing leprosy.
